Last update: March 12, 2021
Throughout the ongoing pandemic, Sanofi has joined forces to develop two vaccine candidates to help prevent and control COVID-19.
Sanofi's two vaccine candidates
Adjuvanted recombinant protein-based vaccine candidate: where do we stand?
mRNA vaccine candidate: where do we stand?
Sanofi and Translate Bio announced on March 12 the start of a phase 1/2 clinical trial for their mRNA COVID-19 vaccine candidate. The study will assess the vaccine candidate’s safety, immune response and reactogenicity with 415 participants to be enrolled across 13 investigational sites.
The joint development team is currently working on improving the temperature stability of the mRNA vaccine candidate to target a -20°C storage temperature for late-stage clinical trials and at launch. Efforts are also underway to enable the vaccine to be stable at routine refrigerator temperature (2-8°C).
“Our mRNA vaccine candidate is the result of our expertise in infectious diseases coupled with the innovative technologies of our partner,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “Initiating the phase 1/2 trial represents an important step forward in our goal of bringing another effective vaccine to the ongoing fight against the COVID-19 pandemic.”
In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants.
Scaling up manufacturing capabilities
Reality safety check
While the urgency of developing an effective vaccine cannot be ignored, Sanofi’s top priority is safety. Our CEO, Paul Hudson, pledged with eight other biopharma CEOs to develop potential vaccines in accordance with high ethical standards and sound scientific principles regarding clinical trials and manufacturing processes.
Only vaccines that have passed an approved phase 3 trial will be submitted for approval or emergency-use authorization, a pledge that “will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved.”
“Our work, as always, is driven by science and our sense of responsibility,” said Paul.
Solidarity is key to moving the fight against COVID-19 forward and, in time, to establishing a blueprint for collaboration and preparation for future pandemics.